MISSION OF AJM PHARMA

AJMirza Pharma & Company's main focus and priority is to bring better healthcare in Pakistan. We believe in providing relief to the people of our country by importing high quality life saving drugs of international standards at cheaper rates. By bringing in our life saving drugs in the market, we are making quality healthcare accessible to all patients. The principals of AJ Mirza Pharma, Cipla, India has 1200 formulations of valuable Life Saving Drugs in the following fields of therapy.

Oncology         ( Anti – Cancer specialties )

HIV / AIDS     ( Antiretrovivals )

Thalassaemia ( Chelation Therapy )

As a result of close follow up by AJM Pharma, the Ministry of Health Pakistan has allowed the import of life saving drugs from India, which were early not permitted. This would make it possible to bring in High quality life saving dugs of international standards at cheaper rates, from Cipla, to meet the medical requirements of the poor patients in Pakistan..  

ABOUT OUR PRINCIPALS – CIPLA

Cipla took birth in 1935 with an ambitious mission to “Care for life.” Seventy years later, through the skills and dedication of its people, the vision of its founder, Khawja Abdul Hameed  has long since come true. The Company has become a front-runner in the  pharmaceutical industry; wielding the latest technology to combat disease and suffering in many ways; touching the lives of thousands the world over.

Facilities – International  Approvals

Cipla products are manufactured in 22 state-of-the-art units. The manufacturing facilities have been approved by the following International Regulatory Agencies.

Food and Drug Administration (FDA), USA

Medicines and Healthcare products Regulatory Agency (MHRA), UK

Therapeutic Goods Administration (TGA), Australia

Medicines Control Council (MCC), South Africa

National Institute of Pharmacy (NIP), Hungary

Pharmaceutical Inspection Convention (PIC), Germany

World Health Organization (WHO)

Department of Health, Canada

State Institute for the Control of Drugs, Slovak Republic ANVISA, Brazil.

Engineering & Quality Control

Cipla is an acknowledged leader in multistage synthesis of complex molecules. The team for drug development, comprising Highly qualified technical personnel, respond to the specific needs of the market and customers, keeping the pipeline extremely robust. In the age, when the mode of delivery is as important as the molecule, Cipla’s rich experience in engineering novel formulations and innovative delivery systems have transformed the management of several acute and chronic diseases.

Sustained and modified release dosage forms.

Inhaled dosage forms

Nasal, rectal and topical preparations

Ready-to-use formulations

Transdermal preparations

Standardized plant-based products

Exports to the world

Over the years Cipla’s Technological supremacy, the relevance and reputation of its product range and its consistent record as a pioneer, have helped the company satisfy demanding markets across continents.

Cipla products are bought by over 149 countries in all continents of the planet earth.. Of the total foreign business, 41% goes to Americas, 24% to Europe, 12 % to the Middle East, 12% to Africa and 11 % to Asia and Australia.

Range of services